Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Total Liabilities (2016 - 2025)

UroGen Pharma (URGN) has disclosed Total Liabilities for 10 consecutive years, with $305.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 3.88% year-over-year to $305.9 million, compared with a TTM value of $305.9 million through Dec 2025, up 3.88%, and an annual FY2025 reading of $305.9 million, up 3.88% over the prior year.
  • Total Liabilities was $305.9 million for Q4 2025 at UroGen Pharma, up from $300.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $305.9 million in Q4 2025 and bottomed at $20.9 million in Q1 2021.
  • Average Total Liabilities over 5 years is $216.4 million, with a median of $234.7 million recorded in 2023.
  • The sharpest move saw Total Liabilities soared 773.63% in 2022, then increased 3.88% in 2025.
  • Year by year, Total Liabilities stood at $111.3 million in 2021, then surged by 102.08% to $225.0 million in 2022, then grew by 8.24% to $243.5 million in 2023, then rose by 20.94% to $294.5 million in 2024, then increased by 3.88% to $305.9 million in 2025.
  • Business Quant data shows Total Liabilities for URGN at $305.9 million in Q4 2025, $300.5 million in Q3 2025, and $302.1 million in Q2 2025.